Quantcast
Home > Quotes > XNCR

Xencor, Inc. Common Stock (XNCR) Quote & Summary Data

XNCR 
$34.27
*  
1.46
4.45%
Get XNCR Alerts
*Delayed - data as of May 21, 2019  -  Find a broker to begin trading XNCR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 34.34 / $ 32.53
Share Volume
160,796
50 Day Avg. Daily Volume
217,984
Previous Close
$ 32.81
52 Week High / Low
$ 48.38 / $ 27.75
Market Cap
1,931,227,145
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
160,796
50 Day Avg. Daily Volume:
217,984

P/E Ratio

P/E Ratio:
52.72
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ 0.65

Trading Range

The current last sale of $34.27 is 23.50% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 34.34 $ 48.38
 Low: $ 32.53 $ 27.75

Company Description (as filed with the SEC)

We are a clinical­stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life­threatening diseases with unmet medical needs. We are developing a suite of clinical-stage drug candidates from our proprietary XmAb® technology platforms that are designed to treat cancer, autoimmune and allergic diseases, and other conditions. In contrast to conventional approaches to antibody design, which focus on the portion of antibodies that interact with target antigens, our protein engineering efforts and the XmAb technologies are focused on the portion of the antibody that interacts with multiple segments of the immune system and controls antibody structure. This portion, referred to as the Fc domain, is constant and interchangeable among antibodies. Our engineered Fc domains, the XmAb technology, can be readily substituted for natural Fc domains.  ... More ...  



Risk Grade

Where does XNCR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 32.98
Open Date:
May 21, 2019
Close Price:
$ 34.27
Close Date:
May 21, 2019


Consensus Recommendation

Analyst Info